December 10, 2013
MPN Research Foundation grantee Robert Kralovics was one of two labs to discover a new genetic mutation that accounts for most of the cases of JAK2 negative MPN patients. Reporting at ASH’s Annual Meeting, Dr. Kralovics revealed the discovery of the Calreticulin, or CALR, mutation in 73% of MPN patients who do not have the JAK2 or MPL mutation.
Click here to read the article published today in the New England Journal of Medicine.
This work was funded in part by a 2011 grant issued to Dr. Kralovics by the MPN Research Foundation. This discovery is predicted to have implications for treatment and diagnosis. We’ll report more as information develops.